Lucerastat (DrugBank: Lucerastat)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 16 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003369-85-NO (EUCTR) | 24/08/2020 | 26/06/2020 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;Italy;Switzerland;United Kingdom;Canada;Belgium;Poland;Australia;Norway;Germany;Netherlands | ||
| 2 | EUCTR2017-003369-85-ES (EUCTR) | 18/05/2020 | 25/05/2020 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Russian Federation;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway | ||
| 3 | EUCTR2017-003369-85-IE (EUCTR) | 18/05/2020 | 01/07/2019 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;Italy;Switzerland;United Kingdom;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway | ||
| 4 | EUCTR2018-002210-12-BE (EUCTR) | 20/03/2020 | 27/03/2020 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway | ||
| 5 | JPRN-JapicCTI-194975 | 01/10/2019 | 27/09/2019 | An multicenter open-label long-term continuous administration study to investigate the safety and tolerability of lucerastat in Japanese Fabry disease patients | An multicenter open-label long-term continuous administration study to investigate the safety and tolerability of lucerastat in Japanese Fabry disease patients | Fabry disease | Intervention name : Lucerastat INN of the intervention : lucerastat Dosage And administration of the intervention : 1000 mg twice daily Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Idorsia Pharmaceuticals Japan Ltd | NULL | other | 16 | BOTH | 20 | Phase 3 | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-JapicCTI-194731 | 30/4/2019 | 24/04/2019 | An open-label phase 3 study of lucerastat in Japanese subjects with Fabry disease | A multicenter, open-label study to determine the efficacy and safety of lucerastat oral therapy in Japanese subjects with Fabry disease | Fabry disease | Intervention name : ACT-434964 INN of the intervention : Lucerastat Dosage And administration of the intervention : 1000mg twice a day, oral administration Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Idorsia Pharmaceuticals Japan Ltd | NULL | complete | 16 | BOTH | 20 | Phase 3 | Japan | |
| 7 | EUCTR2018-002210-12-NL (EUCTR) | 12/04/2019 | 19/11/2018 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;Canada;Belgium;Poland;Australia;Netherlands;Germany;Norway | ||
| 8 | EUCTR2018-002210-12-GB (EUCTR) | 18/03/2019 | 23/10/2018 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Canada;Poland;Belgium;Ireland;Austria;Australia;Netherlands;Germany;United Kingdom | ||
| 9 | EUCTR2018-002210-12-AT (EUCTR) | 19/02/2019 | 05/11/2018 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | France;United States;Czech Republic;Canada;Poland;Australia;Austria;Netherlands;Germany;United Kingdom | |||
| 10 | EUCTR2018-002210-12-DE (EUCTR) | 13/02/2019 | 26/10/2018 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03737214 (ClinicalTrials.gov) | December 18, 2018 | 6/11/2018 | A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease | A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease | Fabry Disease | Drug: Lucerastat | Idorsia Pharmaceuticals Ltd. | NULL | Recruiting | 18 Years | N/A | All | 108 | Phase 3 | United States;Australia;Austria;Belgium;Canada;Germany;Ireland;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;Czechia;France |
| 12 | EUCTR2017-003369-85-NL (EUCTR) | 24/07/2018 | 16/05/2018 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;Italy;Switzerland;United Kingdom;Canada;Belgium;Poland;Australia;Netherlands;Germany;Norway | ||
| 13 | EUCTR2017-003369-85-AT (EUCTR) | 29/06/2018 | 27/04/2018 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;Italy;Switzerland;United Kingdom;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway | ||
| 14 | NCT03425539 (ClinicalTrials.gov) | June 21, 2018 | 16/1/2018 | Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease | A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease | Fabry Disease | Drug: Lucerastat;Drug: Placebo | Idorsia Pharmaceuticals Ltd. | NULL | Recruiting | 18 Years | N/A | All | 99 | Phase 3 | United States;Australia;Austria;Belgium;Canada;Germany;Ireland;Italy;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;Czechia;France |
| 15 | EUCTR2017-003369-85-GB (EUCTR) | 14/05/2018 | 16/04/2018 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02930655 (ClinicalTrials.gov) | February 1, 2015 | 10/10/2016 | A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease | A Single-center, Open-label, Randomized, Versus a Control Group, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral Lucerastat in Adult Subjects With Fabry Disease Receiving Enzyme Replacement Therapy | Fabry Disease | Drug: Lucerastat;Drug: Enzyme replacement therapy (ERT) | Idorsia Pharmaceuticals Ltd. | NULL | Completed | 18 Years | N/A | All | 14 | Phase 1 | Germany |